Cargando…

In vitro and in vivo characterization of [(64)Cu][Cu(elesclomol)] as a novel theranostic agent for hypoxic solid tumors

PURPOSE: Hypoxic tumors are associated with therapy resistance and poor cancer prognosis, but methods to detect and counter tumor hypoxia remain insufficient. Our purpose was to investigate (64)Cu(II)-elesclomol ([(64)Cu][Cu(ES)]) as a novel theranostic agent for hypoxic tumors, by implementing an i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Tengzhi, Dahle, Maria Aanesland, Lystad, Mathilde Hirsum, Marignol, Laure, Karlsen, Morten, Redalen, Kathrine Røe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10547809/ https://www.ncbi.nlm.nih.gov/pubmed/37382663 http://dx.doi.org/10.1007/s00259-023-06310-4

Ejemplares similares

Development of an automated production process of [(64)Cu][Cu (ATSM)] for positron emission tomography imaging and theranostic applications
por: Liu, Tengzhi, et al.
Publicado: (2022)

Hypoxia imaging and theranostic potential of [(64)Cu][Cu(ATSM)] and ionic Cu(II) salts: a review of current evidence and discussion of the retention mechanisms
por: Liu, Tengzhi, et al.
Publicado: (2020)

Harnessing (64)Cu/(67)Cu for a theranostic approach to pretargeted radioimmunotherapy
por: Keinänen, Outi, et al.
Publicado: (2020)

Radionuclide Cisternography with [(64)Cu]Cu-DOTA
por: Greiser, Julia, et al.
Publicado: (2023)

Radiobiological Characterization of (64)CuCl(2) as a Simple Tool for Prostate Cancer Theranostics
por: Guerreiro, Joana Fernandes, et al.
Publicado: (2018)

Potential Production of Theranostic Boron Nitride Nanotubes ((64)Cu-BNNTs) Radiolabeled by Neutron Capture
por: Silva, Wellington Marcos, et al.
Publicado: (2021)

Biokinetic and dosimetric aspects of (64)CuCl(2) in human prostate cancer: possible theranostic implications
por: Righi, Sergio, et al.
Publicado: (2018)

Preclinical Evaluation of a (64)Cu-Based Theranostic Approach in a Murine Model of Multiple Myeloma
por: Métivier, Cassandra, et al.
Publicado: (2023)

Recent Advances in (64)Cu/(67)Cu-Based Radiopharmaceuticals
por: Krasnovskaya, Olga O., et al.
Publicado: (2023)

(64)Cu-ATSM/(64)Cu-Cl(2) and their relationship to hypoxia in glioblastoma: a preclinical study
por: Pérès, Elodie A., et al.
Publicado: (2019)

Comparison of the Effects of DOTA and NOTA Chelators on (64)Cu-Cudotadipep and (64)Cu-Cunotadipep for Prostate Cancer
por: Lee, Inki, et al.
Publicado: (2023)

Multimodal Somatostatin Receptor Theranostics Using [(64)Cu]Cu-/[(177)Lu]Lu-DOTA-(Tyr(3))octreotate and AN-238 in a Mouse Pheochromocytoma Model
por: Ullrich, Martin, et al.
Publicado: (2016)

A digital twin for (64)Cu production with cyclotron and solid target system
por: Isolan, Lorenzo, et al.
Publicado: (2022)

(64)Cu-ATSM and (18)FDG PET uptake and (64)Cu-ATSM autoradiography in spontaneous canine tumors: comparison with pimonidazole hypoxia immunohistochemistry
por: Hansen, Anders E, et al.
Publicado: (2012)

Theranostic (64)Cu-DOTHA(2)-PSMA allows low toxicity radioligand therapy in mice prostate cancer model
por: Milot, Marie-Christine, et al.
Publicado: (2023)

Theragnostic (64)Cu/(67)Cu Radioisotopes Production With RFT-30 Cyclotron
por: Lee, Jun Young, et al.
Publicado: (2022)

[(64)Cu]Cu-DOTATATE PET metrics in the investigation of atherosclerotic inflammation in humans
por: Jensen, Jacob K., et al.
Publicado: (2022)

Hypoxia regulates Notch-3 mRNA and receptor activation in prostate cancer cells
por: Meunier, Armelle, et al.
Publicado: (2016)

Hypoxic Tumor Kinase Signaling Mediated by STAT5A in Development of Castration-Resistant Prostate Cancer
por: Røe, Kathrine, et al.
Publicado: (2013)

(64)Cu-based Radiopharmaceuticals in Molecular Imaging
por: Zhou, Yeye, et al.
Publicado: (2019)

Evaluation of Novel (64)Cu-Labeled Theranostic Gadolinium-Based Nanoprobes in HepG2 Tumor-Bearing Nude Mice
por: Hu, Pengcheng, et al.
Publicado: (2017)

Synthesis and evaluation of (64)Cu-radiolabeled NOTA-cetuximab ((64)Cu-NOTA-C225) for immuno-PET imaging of EGFR expression
por: Xu, Xiaoxia, et al.
Publicado: (2019)

An abbreviated therapy-dosimetric equation for the companion diagnostic/therapeutic [(64/67)Cu]Cu-SARTATE
por: Laffon, Eric, et al.
Publicado: (2021)

In vivo behavior of [(64)Cu]NOTA-terpyridine platinum, a novel chemo-radio-theranostic agent for imaging, and therapy of colorectal cancer
por: Khosravifarsani, Meysam, et al.
Publicado: (2022)

The somatostatin receptor 2 antagonist (64)Cu-NODAGA-JR11 outperforms (64)Cu-DOTA-TATE in a mouse xenograft model
por: Rylova, Svetlana N., et al.
Publicado: (2018)

Focus on the Controversial Aspects of (64)Cu-ATSM in Tumoral Hypoxia Mapping by PET Imaging
por: Colombié, Mathilde, et al.
Publicado: (2015)

Effect of intratumoral administration on biodistribution of (64)Cu-labeled nanoshells
por: Xie, Huan, et al.
Publicado: (2012)

Integrated (64)Cu therapy for the peritoneal dissemination of gastrointestinal cancer
por: Kurihara, Hiroaki
Publicado: (2018)

Pilot Study of (64)Cu(I) for PET Imaging of Melanoma
por: Jiang, Lei, et al.
Publicado: (2017)

(64)Cu-DOTATOC PET-CT in Patients with Neuroendocrine Tumors
por: Mirzaei, Siroos, et al.
Publicado: (2019)

Effect of Liraglutide on Vascular Inflammation Evaluated by [(64)Cu]DOTATATE
por: Zobel, Emilie H., et al.
Publicado: (2021)

[(68)Ga]Ga-NODAGA-E[(cRGDyK)](2) and [(64)Cu]Cu-DOTATATE PET Predict Improvement in Ischemic Cardiomyopathy
por: Follin, Bjarke, et al.
Publicado: (2023)

Tissue acidosis does not mediate the hypoxia selectivity of [(64)Cu][Cu(ATSM)] in the isolated perfused rat heart
por: Baark, Friedrich, et al.
Publicado: (2019)

Molecular Dynamics Study of the Nanoindentation Behavior of Cu(64)Zr(36)/Cu Amorphous/Crystalline Nanolaminate Composites
por: Wu, Wen-Ping, et al.
Publicado: (2021)

Intrathecal [(64)Cu]Cu-albumin PET reveals age-related decline of lymphatic drainage of cerebrospinal fluid
por: Sarker, Azmal, et al.
Publicado: (2023)

Mitochondrial Electron Transport Is the Cellular Target of the Oncology Drug Elesclomol
por: Blackman, Ronald K., et al.
Publicado: (2012)

Elesclomol restores mitochondrial function in genetic models of copper deficiency
por: Soma, Shivatheja, et al.
Publicado: (2018)

Targeted apoptosis of myofibroblasts by elesclomol inhibits hypertrophic scar formation
por: Feng, Yi, et al.
Publicado: (2020)

Oral Elesclomol Treatment Alleviates Copper Deficiency in Animal Models
por: Yuan, Sai, et al.
Publicado: (2022)

Cyclotron-Based Production of (67)Cu for Radionuclide Theranostics via the (70)Zn(p,α)(67)Cu Reaction
por: Brühlmann, Santiago Andrés, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_cu9iansjtqleiphk083oop8p4q